STIM Neuronetics

Neuronetics to Present at the William Blair 43rd Annual Growth Stock Conference

Neuronetics to Present at the William Blair 43rd Annual Growth Stock Conference

MALVERN, Pa., May 24, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “company” or “Neuronetics”), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, announced that the management team will present at the William Blair 43rd Annual Growth Stock Conference on Wednesday, June 7, 2023. The Company is scheduled to present at 1:00 pm Eastern Time the same day via webcast.

A live audio webcast of the presentation will be available online at the investor relations page of the Company’s website at ir.neuronetics.com. A replay of the webcast will be archived on the website for approximately 90 days.

About Neuronetics

Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience and the largest TMS company in the industry, Neuronetics is redefining patient and physician expectations by designing and developing products that improve the quality of life for people suffering from psychiatric disorders. An FDA-cleared, non-drug, noninvasive treatment for people with depression, Neuronetics’ NeuroStar® Advanced Therapy system is today’s leading TMS treatment for MDD with over 5.4 million treatments delivered. NeuroStar is widely researched and backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression outcomes registry. Our NeuroStar® Advanced Therapy system is also FDA-cleared to treat people suffering from obsessive-compulsive disorder, as well as for the treatment of comorbid anxiety symptoms (“anxious depression”) for adults with MDD suffering from anxiety symptoms. Neuronetics is committed to transforming lives by offering an exceptional treatment option that produces extraordinary results. For safety information and indications for use, visit .

Investor Contact:

Mike Vallie or Mark Klausner

ICR Westwicke

443-213-0499

Media Contact:

EvolveMKD

646-517-4220



EN
24/05/2023

Underlying

STIMNeuronetics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Neuronetics

 PRESS RELEASE
Free
STIM NEURONETICS

Neuronetics Comments on Letter from Pointillist Family Office

Neuronetics Comments on Letter from Pointillist Family Office MALVERN, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today issued the following response to the public letter to the Company’s Board of Directors (the “Board”) from Jorey Chernett at Pointillist Family Office published on April 6, 2026: The Board and management team are...

April 7, 2026 1 EN
 PRESS RELEASE
Free
STIM NEURONETICS

Neuronetics Announces Chief Financial Officer Transition

Neuronetics Announces Chief Financial Officer Transition Reaffirms Fiscal Year 2026 Financial Guidance MALVERN, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced that Steven E. Pfanstiel will depart his role as Executive Vice President, Chief Financial Officer, and Treasurer to pursue an opportunity outside the Company....

April 6, 2026 1 EN
 PRESS RELEASE
Free
STIM NEURONETICS

Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Op...

Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results Total revenue of $41.8 million in Q4 2025, up 86% as reported and 23% on an adjusted pro forma basis versus Q4 2024 Greenbrook clinic revenue of $23.5 million in Q4 2025, up 428% as reported and 37% on an adjusted pro forma basis versus Q4 2024 Continued cash management improvement, with cash provided by operations of $0.9 million in Q4 2025 Expect full year 2026 revenue of between $160 million and $166 million Dan Reuvers appointed as President and Chief Executive Officer, effective March 23, 2026; pr...

March 17, 2026 1 EN
 PRESS RELEASE
Free
STIM NEURONETICS

Neuronetics Appoints Dan Reuvers as President and Chief Executive Offi...

Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer Seasoned leader brings more than 30 years of medical device experience, with a proven track record of growing revenue, earnings, and cash flow across multiple publicly traded healthcare companies MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today an...

March 17, 2026 1 EN
 PRESS RELEASE
Free
STIM NEURONETICS

Neuronetics to Report Fourth Quarter 2025 Financial and Operating Resu...

Neuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it plans to release fourth quarter 2025 financial and operating results prior to market open on Tuesday, March 17, 2026....

March 3, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch